Lorain City Clerk Ted Kalo vows to keep the momentum going that he started when he first got the position seven years ago. “We’re going to keep with the innovation and stay up tot date on it,” Kalo ...
Novartis is just months away from filing for approval of oral BTK inhibitor remibrutinib as a treatment for chronic spontaneous urticaria – also known as chronic hives – after reporting long-term data ...
REMIX - Standpoint Multi-Asset Investor - Review the REMIX stock price, growth, performance, sustainability and more to help you make the best investments.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback